scispace - formally typeset
Open AccessJournal ArticleDOI

Virological suppression in children and adolescents is not influenced by genotyping, but depends on optimal adherence to antiretroviral therapy

TLDR
Despite the use of genotyping tests in guidance of a more effective antiretroviral regimen, poor adherence to ART seems to be the main determinant of low virological suppression rate for children and adolescents, in Salvador, Brazil.
Abstract
Objective To evaluate the virological outcomes in children and adolescents infected with HIV-1 in Salvador, Bahia according to genotyping results. Methods We retrospectively evaluated the rates of virological suppression of children and adolescents submitted to HIV-1 genotyping test from January/2008 to December/2012. The participants were followed in the two referral centers for pediatric AIDS care, in Salvador, Brazil. Resistance mutations, drug sensitivity profiles, and viral subtypes were analyzed using the Stanford HIV-1 Drug Resistance Database. Adherence was estimated by drugs withdrawal at pharmacies of the two sites. Results 101 subjects were included: 35 (34.6%) were drug-naive, and the remaining 66 were failing ART. In drug-naive group, 3 (8.6%), presented with NNRTIs resistance mutations, along with polymorphic mutations to PIs in most (82.8%) of them. Among the failing therapy group, we detected a high frequency (89.4%) of resistance mutations to PIs, NRTI (84.8%), and NNRTI (59.1%). Virological suppression after introduction/modification of genotyping-guided ART was achieved only for patients (53.1%) with drug withdrawal over 95%. Main detected HIV-1 subtypes were B (67.3%), F (7.9), C (1.9%), and recombinant forms (22.9%). Conclusions Despite the use of genotyping tests in guidance of a more effective antiretroviral regimen, poor adherence to ART seems to be the main determinant of low virological suppression rate for children and adolescents, in Salvador, Brazil.

read more

Content maybe subject to copyright    Report

Citations
More filters
Journal ArticleDOI

Factors associated with virological non-suppression among HIV-positive children receiving antiretroviral therapy at the Joint Clinical Research Centre in Lubowa, Kampala Uganda.

TL;DR: In this paper, the authors determined the factors associated with virological non-suppression among children living with HIV receiving ART at a peri-urban HIV care clinic in Kampala, Uganda.
Journal ArticleDOI

Drug resistance and optimizing dolutegravir regimens for adolescents and young adults failing antiretroviral therapy.

TL;DR: In 1st-line failure, implementation of TLD for many adolescents and young adults on long-term ART may require additional active drug(s) and drug resistance surveillance and susceptibility scores may inform strategies for the implementation ofTLD.
Journal ArticleDOI

HIV‐1 subtype frequency in Northeast Brazil: A systematic review and meta‐analysis

TL;DR: Although subtype B is predominant in Brazil, a large frequency of non‐B subtypes has also been found, which may have consequences for response to antiretroviral therapy, disease progression, and transmission.
References
More filters
Journal ArticleDOI

HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy

TL;DR: Results lead to a simple steady-state model in which infection, cell death, and cell replacement are in balance, and imply that the unique feature of HIV is the extraordinarily large number of replication cycles that occur during infection of a single individual.

Antiretroviral Drug Resistance Testing in Adult HIV-1 Infection

TL;DR: Emerging data indicate that despite limitations, resistance testing should be incorporated into patient management in some settings, and resistance testing is recommended to help guide the choice of new regimens after treatment failure and for guiding therapy for pregnant women.
Journal ArticleDOI

Drug-resistance genotyping in HIV-1 therapy: the VIRAD APT randomi sed controlled trial

TL;DR: Genotypic-resistance testing is found to have a significant benefit on the virological response when choosing a therapeutic alternative for HIV-1-infected patients in whom combination therapy was not successful.
Related Papers (5)